TG01 IND application filed in China by Circio’s partner IOVaxis Therapeutics
· The updated TG01 IND application has been filed with the Chinese NMPA, triggering a sixty-day review period · Following IND acceptance, IOVaxis has a two-week window to exercise its exclusive TG01 license option for clinical development and commercialization in Greater China and Singapore Oslo, Norway 12 December 2023 – Circio Holding ASA (OSE: CRNA) announces that partner IOVaxis Therapeutics of Nantong, China, has filed the updated TG01 investigational new drug (IND) application with the Chinese National Medical Products Administration (NMPA), with an expected review period of